0001209191-17-044153.txt : 20170706
0001209191-17-044153.hdr.sgml : 20170706
20170706171852
ACCESSION NUMBER: 0001209191-17-044153
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170703
FILED AS OF DATE: 20170706
DATE AS OF CHANGE: 20170706
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mersana Therapeutics, Inc.
CENTRAL INDEX KEY: 0001442836
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-498-0020
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC
DATE OF NAME CHANGE: 20080813
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MOTT DAVID M
CENTRAL INDEX KEY: 0001219871
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38129
FILM NUMBER: 17953203
MAIL ADDRESS:
STREET 1: 1119 ST. PAUL STREET
CITY: BALTIMORE
STATE: MD
ZIP: 21202
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-07-03
0
0001442836
Mersana Therapeutics, Inc.
MRSN
0001219871
MOTT DAVID M
1954 GREENSPRING DRIVE
SUITE 600
TIMONIUM
MD
21093
1
0
1
0
Common Stock
2017-07-03
4
C
0
7140138
A
7140138
I
See Note 3
Common Stock
2017-07-03
4
P
0
1000000
15.00
A
8140138
I
See Note 3
Series A-1 Preferred Stock
2017-07-03
4
C
0
11931173
0.00
D
Common Stock
2647241
0
I
See Note 3
Series B-1 Preferred Stock
2017-07-03
4
C
0
18001419
0.00
D
Common Stock
4000314
0
I
See Note 3
Series C-1 Preferred Stock
2017-07-03
4
C
0
2216626
0.00
D
Common Stock
492583
0
I
See Note 3
The total represents shares received upon conversion of Series A-1, Series B-1 and Series C-1 Convertible Preferred Stock.
Upon closing of the Issuer's initial public offering, each share of Series A-1, Series B-1 and Series C-1 Convertible Preferred Stock automatically converted into .22222 shares of Common Stock without payment of further consideration. There was no expiration date for the Series A-1, Series B-1 or Series C-1 Convertible Preferred Stock.
The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.
/s/ Sasha Keough, attorney-in-fact
2017-07-06